ANTI INFECTIVE

Alkem, Biosergen to develop anti-infective for severe fungal infections

Alkem will manage the first clinical patient trial, which is expected to start immediately after the regulatory approval. The trial will enrol patients suffering from severe fungal infections such as mucormycosis (black fungus), aspergillosis, and candidiasis, who are intolerant or resistant to Amphotericin B.